Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-23T09:34:35.823Z Has data issue: false hasContentIssue false
  • English
  • Français

Value of the MoCA Test as a Screening Instrument in Multiple Sclerosis

Published online by Cambridge University Press:  23 September 2014

Emmanuelle Dagenais ,
Isabelle Rouleau ,
Mélanie Demers ,
Céline Jobin ,
Élaine Roger ,
Laury Chamelian  and
Pierre Duquette
Emmanuelle Dagenais
Affiliation:
Department of Psychology, Université du Québec à Montréal
Isabelle Rouleau*
Affiliation:
Neurology Service, Hôpital Notre-Dame du CHUM
Mélanie Demers
Affiliation:
Department of Psychology, Université du Québec à Montréal
Céline Jobin
Affiliation:
Neurology Service, Hôpital Notre-Dame du CHUM Neurology Service, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada
Élaine Roger
Affiliation:
Neurology Service, Hôpital Notre-Dame du CHUM
Laury Chamelian
Affiliation:
Department of Psychiatry, Hôpital Notre-Dame du CHUM
Pierre Duquette
Affiliation:
Neurology Service, Hôpital Notre-Dame du CHUM
*
Department of Psychology, Université du Québec à Montréal, CP 8888, Succ. Centre-ville, Montréal, Québec, H3C 3P8, Canada. Email: rouleau.isabelle@uqam.ca
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

Since a large proportion of multiple sclerosis (MS) patients exhibit cognitive deficits, it is important to have reliable and cost-effective screening measures that can be used to follow patients effectively. the objective of this study was to evaluate the clinical value of the Montreal Cognitive Assessment (MoCA) test in detecting cognitive deficits in MS patients.

Methods:

Forty-one (70.1% women, mean age 44.51 ±7.43) mildly impaired (EDSS: 2.26 ±1.87) MS patients were recruited for this study. In addition to the MoCA, they were administered the MSNQ-P (patient version) and the MSNQ-I (informant version), the bDI-FS and a comprehensive neuropsychological test battery.

Results:

there were significant correlations between the MoCA test and the three factors derived from the neuropsychological evaluation (Executive/speed of processing, Learning, Delayed recall). the MoCA test was correlated with the MSNQ-I but only marginally with the MSNQ-P. In addition, there was no significant correlation between the MSNQ-P and the neuropsychological factors, whereas significant correlations were found between two of those factors (Learning and Delayed recall) and the MSNQ-I, suggesting that the informant version is more reliable than the patient version for the presence of cognitive deficits.

Conclusion:

the results obtained in the present study support the value of the MoCA test as a screening tool for the presence of cognitive dysfunction in MS patients, even in patients with mild functional disability (EDSS).

Résumé:

Résumé:Objectif:

Étant donné qu'une grande proportion des patients atteints de sclérose en plaques (SP) présentent des déficits cognitifs, il est important d'utiliser des mesures de dépistage fiables et économiques pour suivre ces patients efficacement. Le but de cette étude était d'évaluer la valeur clinique du MoCA pour détecter un déficit cognitif chez les patients atteints de SP.

Méthode:

Quarante et un patients atteints de SP avec déficit cognitif léger, dont 70,1% étaient des femmes et dont l'âge moyen était de 44,51 ± 7,43 ans, ont été inclus dans l'étude. En plus du MoCA, le MSNQ-P (version patient) et le MSNQ-I (version informateur), le bDI-FS et une batterie de tests neuropsychologiques ont été administrés aux patients.

Résultats:

Nous avons noté une corrélation significative entre le test MoCA et les trois facteurs dérivés de l'évaluation neuropsychologique (les fonctions exécutives/la vitesse du traitement de l'information, l'apprentissage, le rappel différé). Le MoCa était corrélé au MSNQ-I, mais seulement de façon marginale au MSNQ-P. De plus, il n'y avait pas de corrélation significative entre le MSNQ-P et les facteurs neuropsychologiques, alors que des corrélations significatives étaient présentes entre deux de ces facteurs (l'apprentissage et le rappel différé) et le MSNQ-I, ce qui suggère que la version informateur est plus fiable que la version patient en ce qui a trait à la présence de déficits cognitifs.

Conclusion:

Selon les résultats de cette étude, le test MoCA est un outil de dépistage utile pour mettre en évidence la présence d'une dysfonction cognitive chez les patients atteints de SP, même chez ceux qui présentent une invalidité fonctionnelle légère (EDSS).

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 40 , Issue 3 , May 2013 , pp. 410 - 415
Copyright
Copyright © The Canadian Journal of Neurological 2013

References

1. Chiaravalloti, ND, DeLuca, J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008;7(12):1139–51.CrossRefGoogle ScholarPubMed
2. Thornton, AE, Raz, N. Memory impairment in multiple sclerosis: a quantitative review. Neuropsychology. 1997;11(3):357–66.CrossRefGoogle ScholarPubMed
3. Edgar, C, Jongen, PJ, Sanders, E, et al. Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery. bMC Neurol. 2011;11:68.CrossRefGoogle ScholarPubMed
4. Winkelmann, A, Engel, C, Apel, A, Zettl, UK. Cognitive impairment in multiple sclerosis. J Neurol. 2007;254 Suppl 2:II35–42.CrossRefGoogle ScholarPubMed
5. Ouellet, J, Scherzer, Pb, Rouleau, I, et al. Assessment of social cognition in patients with multiple sclerosis. J Int Neuropsychol Soc. 2010;16(2):287–96.CrossRefGoogle ScholarPubMed
6. Rao, SM, Leo, GJ, Ellington, L, Nauertz, T, Bernardin, L, Unverzagt, F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology. 1991;41(5):692–6.Google Scholar
7. Benedict, RH, Munschauer, F, Linn, R, et al. Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult Scler. 2003;9(1):95–101.CrossRefGoogle ScholarPubMed
8. Scherer, P. Cognitive screening in multiple sclerosis. J Neurol. 2007;254 Suppl 2:II26–9.Google Scholar
9. Benedict, RH, Zivadinov, R. Reliability and validity of neuropsychological screening and assessment strategies in MS. J Neurol. 2007;254 Suppl 2:II22–II5.CrossRefGoogle ScholarPubMed
10. O’brien, A, Gaudino-Goering, E, Shawaryn, M, Komaroff, E, Moore, NB, DeLuca, J. Relationship of the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) to functional, emotional, and neuropsychological outcomes. Arch Clin Neuropsychol. 2007;22(8):933–48.CrossRefGoogle ScholarPubMed
11. Benedict, RH, Fishman, I, McClellan, MM, Bakshi, R, Weinstockguttman, B. validity of the beck Depression Inventory-Fast Screen in multiple sclerosis. Mult Scler. 2003;9(4):393–6.Google Scholar
12. Benedict, RH, Zivadinov, R. Predicting neuropsychological abnormalities in multiple sclerosis. J Neurol Sci. 2006;245(1-2):67–72.Google Scholar
13. Demers, M, Rouleau, I, Scherzer, P, Ouellet, J, Jobin, C, Duquette, P. Impact of the cognitive status on the memory complaints in MS patients. Can J Neurol Sci. 2011;38(5):728–33.Google Scholar
14. Nasreddine, ZS, Phillips, NA, Bedirian, V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.Google Scholar
15. Folstein, MF, Robins, LN, Helzer, JE. The Mini-Mental State Examination. Arch Gen Psychiatry. 1983;40(7):812.Google Scholar
16. Ismail, Z, Rajji, TK, Shulman, KI. Brief cognitive screening instruments: an update. Int J Geriatr Psychiatry. 2010;25(2):111–20.Google Scholar
17. Beatty, WW, Goodkin, DE. Screening for cognitive impairment in multiple sclerosis. An evaluation of the Mini-Mental State Examination. Arch Neurol. 1990;47(3):297–301.Google Scholar
18. Polman, CH, Reingold, SC, Edan, G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58(6):840–6.Google Scholar
19. Durand, MJ, Vachon, B, Hong, QN, Imbeau, D, Amick, BC 3rd, Loisel, P. The cross-cultural adaptation of the Work Role Functioning Questionnaire in Canadian French. Int J Rehabil Res. 2004;27 (4):261–8.Google Scholar
20. Fisk, JD, Pontefract, A, Ritvo, PG, Archibald, CJ, Murray, TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci. 1994;21(1):9–14.CrossRefGoogle ScholarPubMed
21. Buysse, DJ, Reynolds, CF 3rd, Monk, TH, Berman, SR, Kupfer, DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.CrossRefGoogle ScholarPubMed
22. Johns, MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–5.Google Scholar
23. Snaith, RP. The Hospital Anxiety and Depression Scale. Health Qual Life Outcomes. 2003;1:29.CrossRefGoogle ScholarPubMed
24. Benedict, RH, Bruce, JM, Dwyer, MG, et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol. 2006;63(9):1301–6.Google Scholar
25. Rao, SM, Leo, GJ, Bernardin, L, Unverzagt, F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991;41(5):685–91.Google Scholar
26. Benedict, RH, Fischer, JS, Archibald, CJ, et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol. 2002;16(3):381–97.CrossRefGoogle ScholarPubMed
27. Lezak, MD, Howieson, DB, Bigler, D, Tranel, D. Neuropsychological Assessment. 5th ed. New-York: Oxford University Press; 0.Google Scholar
28. Benedict, RH, Carone, DA, Bakshi, R. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. J Neuroimaging. 2004;14(3 Suppl):36S–45S.Google Scholar
29. Videnovic, A, Bernard, B, Fan, W, Jaglin, J, Leurgans, S, Shannon, KM. The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease. Mov Disord. 2010;25(3):401–4.CrossRefGoogle ScholarPubMed
30. Gill, DJ, Freshman, A, Blender, JA, Ravina, B. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov Disord. 2008;23(7): 1043–6.Google Scholar
31. Hoops, S, Nazem, S, Siderowf, AD, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73(21):1738–45.Google Scholar
32. Schweizer, TA, Al-Khindi, T, Macdonald, RL. Mini-Mental State Examination versus Montreal Cognitive Assessment: rapid assessment tools for cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. J Neurol Sci. 2012;316 (1-2):137–40.Google Scholar
33. Godefroy, O, Fickl, A, Roussel, M, et al. Is the Montreal Cognitive Assessment superior to the Mini-Mental State Examination to detect poststroke cognitive impairment? A study with neuropsychological evaluation. Stroke. 2011;42(6):1712–16.Google Scholar
34. Cameron, J, Worrall-Carter, L, Page, K, Stewart, S, Ski, CF. Screening for mild cognitive impairment in patients with heart failure: Montreal Cognitive Assessment versus Mini Mental State Exam. Eur J Cardiovasc Nurs. 2012. [Epub ahead of print]Google Scholar
35. Ggagnon, JF, Postuma, RB, Joncas, S, Desjardins, C, Latreille, V. The Montreal Cognitive Assessment: a screening tool for mild cognitive impairment in REM sleep behavior disorder. Mov Disord. 2010;25(7):936–40.Google Scholar
36. Benedict, RH, Cox, D, Thompson, LL, Foley, F, Weinstock-Guttman, B, Munschauer, F. Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler. 2004;10(6):675–8.Google Scholar